Evidence map›Paper›PMID 36895800›Full record

ArticleEClinicalMedicine2023

Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort study.

Neha Korde, Elizabet Tavitian, Donna Mastey, Joseph Lengfellner, Gil Hevroni, Andrew Zarski, Meghan Salcedo, Sham Mailankody, Hani Hassoun, Eric L Smith and 17 more

Abstract read
In one paragraph

Article in EClinicalMedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Neha KordeMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Elizabet TavitianMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Donna MasteyMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Joseph LengfellnerResearch and Technology Management, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Gil HevroniDepartment of Medicine, SUNY Downstate, New York, NY, USA.
Andrew ZarskiResearch and Technology Management, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Meghan SalcedoMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sham MailankodyMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hani HassounMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Eric L SmithDana Farber Cancer Institute, Boston, MA, USA.
Malin HultcrantzMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Urvi ShahMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Carlyn TanMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Benjamin DiamondMyeloma Service, University of Miami, FL, USA.
Gunjan ShahAdult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michael ScordoAdult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Oscar LahoudAdult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
David J ChungAdult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Heather LandauAdult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sergio GiraltAdult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Andriy DerkachBiostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Thomas M AtkinsonDepartment of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Paul SabbatiniDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Francesca KönigDepartment of Physical Medicine & Rehabilitation, University of Colorado Medicine, Aurora, CO, USA.
Saad Z UsmaniMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ola LandgrenMyeloma Service, University of Miami, FL, USA.
Alexander M LesokhinMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
UM Calabresi Clinical Oncology Research Career Development AwardK12CA226330 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Alan Pollack · 2018 to 2026
$5.1M
NCI NIH HHS K12 CA226330NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Background: Due to the nature of their disease, patients with multiple myeloma (MM) often have bone disease-related pain that limits physical activity and diminishes health-related quality of life (HRQOL). Digital health technology with wearables and electronic patient reported outcome (ePRO) tools can provide insights into MM HRQoL. Methods: In this prospective observational cohort study conducted at Memorial Sloan Kettering Cancer in NY, NY, USA, patients with newly diagnosed MM (n = 40) in two cohorts (Cohort A - patients <65 years; Cohort B - patients ≥65 years) were passively remote-monitored for physical activity at baseline and continuously for up to 6 cycles of induction therapy from Feb 20, 2017 to Sep 10, 2019. The primary endpoint of the study was to determine feasibility of continuous data capture, defined as 13 or more patients of each 20-patient cohort compliant with capturing data for ≥16 h of a 24-hr period in ≥60% of days of ≥4 induction cycles. Secondary aims explored activity trends with treatment and association to ePRO outcomes. Patients completed ePRO surveys (EORTC - QLQC30 and MY20) at baseline and after each cycle. Associations between physical activity measurements, QLQC30 and MY20 scores, and time from the start of treatment were estimated using a linear mixed model with a random intercept. Findings: Forty patients were enrolled onto study, and activity bioprofiles were compiled among 24/40 (60%) wearable user participants (wearing the device for at least one cycle). In an intention to treat feasibility analysis, 21/40 (53%) patients [12/20 (60%) Cohort A; 9/20 (45%) Cohort B] had continuous data capture. Among data captured, overall activity trended upward cycle over cycle for the entire study cohort (+179 steps/24 h per cycle; p = 0.0014, 95% CI: 68-289). Older patients (age ≥65 years) had higher increases in activity (+260 steps/24 h per cycle; p < 0.0001, 95% CI: -154 to 366) compared to younger patients (+116 steps/24 h per cycle; p = 0.21, 95% CI: -60 to 293). Activity trends associated with improvement of ePRO domains, including physical functioning scores (p < 0.0001), global health scores (p = 0.02), and declining disease burden symptom scores (p = 0.042). Interpretation: Our study demonstrates that feasibility of passive wearable monitoring is challenging in a newly diagnosed MM patient population due to patient use. However, overall continuous data capture monitoring remains high among willing user participants. As therapy is initiated, we show improving activity trends, mainly in older patients, and that activity bioprofiles correlate with traditional HRQOL measurements. Funding: Grants -National Institutes of HealthP30 CA 008748, Awards - Kroll Award 2019.

Indexed as

Health related quality of lifemHealthMultiple myelomaWearable technology

Identifiers

PMID36895800
PMCPMC9989635

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.